Kong Xiang-yu, Hao Yuan, Wu Tai-xiang, Xie Yan-ming
Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Zhong Xi Yi Jie He Xue Bao. 2010 Dec;8(12):1124-32. doi: 10.3736/jcim20101204.
Chaihu Injection (CI), which is widely used in treatment of febrile diseases, is an aqueous solution of Chaihu (Radix Bupleuri Chinensis) or Nanchaihu (Radix Bupleuri Scorzonerifolii) prepared by steam distillation.
This study aims at finding out the possible causes for adverse drug reaction or adverse event (ADR/AE) caused by CI and assessing its safety based on existing evidence.
Manual search was not conducted. Electronic search was conducted by two authors in China National Knowledge Internet (CNKI) database and Chongqing VIP database (VIP). The search ended in June 30th, 2009.
Studies of ADR/AE induced by CI were collected comprehensively without considering language of literature and outcome indicators. Search results were not limited by patient's age, gender, race, primary disease, etc. Interventions were using CI alone or CI combined with other drugs (Chinese herbal medicine decoction or other drugs containing Chaihu were excluded).
Two authors conducted data extraction independently. Microsoft Excel software was used to develop data extraction forms. Because of heterogeneity of the studies, only a descriptive analysis was conducted.
Totally 83 studies with 203 cases were included in this review. Without the yield data and total amount of using, we cannot tell the incidence of ADR/AE induced by CI as well as assess the risk and safety of CI. The constituent ratio of severe cases was higher in children and old people than in other age groups. For most intramuscular cases, ADR/AE happened in 30 min after injection (constituent ratio of cumulative incidence in 30 min was 93.8%); for intravenously guttae patients, 4 cases of ADR/AE happened in the process of infusion; for first users, constituent ratio of cumulative incidence in 30 min and constituent ratio of cumulative incidence of severe cases in 30 min were higher than cases who had used CI before. Most ADRs/AEs were caused by incorrect use of CI, such as excessive doses (5 cases), intravenously guttae administration (6 cases), and violating incompatibility rules (7 cases). The incidence ratios of ADR and AE for severe and mild cases were 1.7:1 and 1.1:1, respectively; the ratios of the three relevant levels described as definitely related, most probably related and possibly related in the two types (severe and mild) of cases were 25:14:5 and 44:9:16, respectively.
Present evidence with low level shows that incorrect use is the main cause of ADR/AE of CI. Whether CI is proper for children and old people still needs further research. Training for correct use of CI is necessary for medical workers. Much improvement in reporting ADR/AE based on "Recommendations for Reporting Adverse Drug Reactions and Adverse Events of Traditional Chinese Medicine" is in need.
柴胡注射液(CI)是由柴胡(北柴胡)或南柴胡经水蒸气蒸馏制成的水溶液,广泛用于治疗发热性疾病。
本研究旨在找出CI引起药物不良反应或不良事件(ADR/AE)的可能原因,并根据现有证据评估其安全性。
未进行手工检索。由两位作者在中国知网(CNKI)数据库和重庆维普数据库(VIP)进行电子检索。检索截至2009年6月30日。
全面收集CI所致ADR/AE的研究,不考虑文献语言和结局指标。检索结果不受患者年龄、性别、种族、原发疾病等限制。干预措施为单独使用CI或CI与其他药物联合使用(排除中药汤剂或其他含柴胡的药物)。
两位作者独立进行数据提取。使用Microsoft Excel软件制作数据提取表格。由于研究的异质性,仅进行描述性分析。
本综述共纳入83项研究,203例病例。由于缺乏产量数据和使用总量,我们无法得知CI所致ADR/AE的发生率,也无法评估CI的风险和安全性。儿童和老年人严重病例的构成比高于其他年龄组。对于大多数肌肉注射病例,ADR/AE发生在注射后30分钟内(30分钟内累计发生率的构成比为93.8%);对于静脉滴注患者,4例ADR/AE发生在输液过程中;对于首次使用者,30分钟内累计发生率的构成比和30分钟内严重病例累计发生率的构成比高于既往使用过CI的病例。大多数ADR/AE是由于CI使用不当引起的,如剂量过大(5例)、静脉滴注给药(6例)和违反配伍禁忌规则(7例)。严重和轻度病例的ADR和AE发生率之比分别为1.7:1和1.1:1;两种类型(严重和轻度)病例中明确相关、很可能相关和可能相关这三个相关程度的比例分别为25:14:5和44:9:16。
现有低水平证据表明,使用不当是CI所致ADR/AE的主要原因。CI对儿童和老年人是否适用仍需进一步研究。对医务人员进行CI正确使用培训很有必要。基于《中药不良反应和不良事件报告指南》在ADR/AE报告方面急需大幅改进。